Abstract
BP180, also termed collagen XVII, is a hemidesmosomal transmembrane glycoprotein expressed in basal keratinocytes, and functions as a cell–matrix adhesion molecule in the dermal–epidermal junction of the skin. Its function, other than cell–matrix adhesion, remains unclear. We generated a mouse strain with BP180 dysfunction (termed ∆NC16A), which develops spontaneous skin inflammation accompanied by an influx of myeloid derived suppressor cells (MDSCs). We used the B16 mouse melanoma model to demonstrate that BP180 dysfunction in either skin or basal keratinocytes promotes MDSC influx into skin and tumor progression. MDSC depletion reduced tumor progression in ∆NC16A mice, demonstrating a critical role for BP180 dysfunction-driven MDSCs in melanoma progression. This study provides the first direct evidence that BP180, a cell–cell matrix adhesion molecule, possesses antitumor function through modulating infiltration of MDSCs. Basal keratinocytes actively participate in skin microenvironment changes caused by BP180 dysfunction. ∆NC16A mice could be a new animal model to study the melanoma microenvironment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hammers CM, Stanley JR. Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol Mech Dis. 2016;11:175–97.
Koster J, Geerts D, Favre B, Borradori L, Sonnenberg A. Analysis of the interactions between BP180, BP230, plectin and the integrin alpha6beta4 important for hemidesmosome assembly. J Cell Sci. 2003;116:387–99.
Hopkinson SB, Jones JC. The N terminus of the transmembrane protein BP180 interacts with the N-terminal domain of BP230, thereby mediating keratin cytoskeleton anchorage to the cell surface at the site of the hemidesmosome. Mol Biol Cell. 2000;11:277–86.
Margadant C, Frijns E, Wilhelmsen K, Sonnenberg A. Regulation of hemidesmosome disassembly by growth factor receptors. Curr Opin Cell Biol. 2008;20:589–96.
Leighty L, Li N, Diaz LA, Liu Z. Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid. Arch Dermatol Res. 2007;299:417–22.
McGrath JA, Galalica B, Christiano AM, Li K, Owaribe K, McMillian JR, et al. Mutation in the 180-kD bulleus pemphigoid antigen (BPAG2), a hemidesmosomal transmembreane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat Genet. 1995;11:83–6.
Van den Bergh F, Eliason SL, Burmeister BT, Giudice GJ. Collagen XVII (BP180) modulates keratinocyte expression of the proinflammatory chemokine, IL-8. Exp Dermatol. 2012;21:605–11.
Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Investig Dermatol. 1992;99:243–50.
Nishie W, Sawamura D, Goto M, Ito K, Shibaki A, McMillan JR, et al. Humanization of autoantigen. Nat Med. 2007;13:378–83.
Liu Z, Sui W, Zhao M, Li Z, Li N, Thresher R, et al. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun. 2008;31:331–8.
Jonkman MF, Jong MCJM De, Heeres K, Pas HH, Meer JB Van Der, Owaribe K et al. 180-kD Bullous Pemphigoid Antigen (BP180) is deficient in generalized atrophic benign epidermolysis bullosa. 1982;1345–52.
Hurskainen T, Moilanen J, Sormunen R, Franzke C-W, Soininen R, Loeffek S, et al. Transmembrane collagen XVII is a novel component of the glomerular filtration barrier. Cell Tissue Res. 2012;348:579–88.
Tanimura S, Tadokoro Y, Inomata K, Binh NT, Nishie W, Yamazaki S, et al. Hair follicle stem cells provide a functional niche for melanocyte stem cells. Cell Stem Cell 2011;8:177–87.
Matsumura H, Mohri Y, Binh NT, Morinaga H, Fukuda M, Ito M, et al. Hair follicle aging is driven by transepidermal elimination of stem cells via COL17A1 proteolysis. Science. 2016;351:1–14.
Parikka M, Kainulainen T, Tasanen K, Väänänen A, Bruckner-Tuderman L, Salo T. Alterations of collagen XVII expression during transformation of oral epithelium to dysplasia and carcinoma. J Histochem Cytochem. 2003;51:921–9.
Parikka M, Nissinen L, Kainulainen T, Bruckner-Tuderman L, Salo T, Heino J, et al. Collagen XVII promotes integrin-mediated squamous cell carcinoma transmigration—a novel role for αIIb integrin and tirofiban. Exp Cell Res. 2006;312:1431–8.
Stelkovics E, Korom I, Marczinovits I, Molnar J, Rasky K, Raso E, et al. Collagen XVII/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy. Appl Immunohistochem Mol Morphol. 2008;16:433–41.
Parikka M. Altered expression of collagen XVII in ameloblastomas and basal cell carcinomas. J Oral Pathol. 2001;589–95.
Krenacs T, Kiszner G, Stelkovics E, Balla P, Teleki I, Nemeth I, et al. Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis. Histochem Cell Biol. 2012;138:653–67.
Golan T, Messer AR, Amitai-Lange A, Melamed Z, Ohana R, Bell RE, et al. Interactions of melanoma cells with distal keratinocytes trigger metastasis via notch signaling inhibition of MITF. Mol Cell. 2015;59:664–76.
Zhang Y, Hwang B-J, Liu Z, Li N, Lough K, Williams SE, et al. BP180 dysfunction triggers spontaneous skin inflammation in mice. Proc Natl Acad Sci USA. 2018;115:6434–9.
Hanahan D, Weinberg RA, Pan KH, Shay JW, Cohen SN, Taylor MB, et al. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073–81.
Hurskainen T, Kokkonen N, Sormunen R, Jackow J, Löffek S, Soininen R et al. Deletion of the major bullous pemphigoid epitope region of collagen XVII induces blistering, autoimmunization, and itching in mice. J Investig Dermatol. 2014;1–8.
Aho S, Uitto J. 180-kD bullous pemphigoid antigen/Type XVII collagen: tissue-specific expression and molecular interactions with keratin 18. 1999;367:356–67.
Di Meglio P, Perera GK, Nestle FO. The multitasking organ: recent insights into skin immune function. Immunity. 2011;35:857–69.
Bangert C, Brunner PM, Stingl G. Immune functions of the skin. Clin Dermatol. 2011;29:360–76.
Van Kilsdonk JWJ, Bergers M, Van Kempen LC, Schalkwijk GWM, Swart GWM. Keratinocytes drive melanoma invasion in a reconstructed skin model. Melanoma Res. 2010;20:372–80.
Tang L, Wang K. Chronic inflammation in skin malignancies. J Mol Signal. 2016;11:1–13.
Ortiz ML, Kumar V, Martner A, Mony S, Donthireddy L, Condamine T, et al. Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17–producing CD4+ T cells. J Exp Med. 2015;212:351–67.
Lund AW, Medler TR, Leachman SA, Coussens LM. Lymphatic vessels, inflammation, and immunity in skin cancer. Cancer Discov. 2016;6:22–35.
Bleehen S. Normal pigmentation, radiation and response to sun exposure. In: Champion R, Burns D, Breathnach S, editors. Textbook of dermatology. London: Blackwell-Science; 1998. p. 1765–7.
Silvers WK. The coat colors of mice: a model for mammalian gene action and interaction. In: Altman PL, K DD, editors. Inbred and genetically defined strains of laboratory animals, Part1 Mouse and rat. New York: Springer-Verlag; 1979. p. 1979.
Rozenberg GI, Monahan KB, Torrice C, Bear JE, Sharpless NE. Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation. Melanoma Res. 2010;20:361–71.
Bobek V, Kolostova K, Pinterova D, Kacprzak G, Adamiak J, Kolodziej J, et al. A clinically relevant, syngeneic model of spontaneous, highly metastatic B16 mouse melanoma. Anticancer Res. 2010;30:4799–804.
Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37:208–20.
Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008;111:5457–66.
Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13:739–52.
Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181:5791–802.
Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.
Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618–31.
Condamine T, Ramachandran I, Youn J-I, Gabrilovich DI. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med. 2015;66:97–110.
Ostrand-Rosenberg S, Sinha P. MDSCs: linking inflammation and cancer. J Immunol. 2009;182:4499–506.
Parikka M, Nissinen L, Kainulainen T, Bruckner-Tuderman L, Salo T, Heino J, et al. Collagen XVII promotes integrin-mediated squamous cell carcinoma transmigration—a novel role for alphaIIb integrin and tirofiban. Exp Cell Res. 2006;312:1431–8.
Fine J-D. Inherited epidermolysis bullosa. Orphanet J Rare Dis. 2010;5:561–8.
Bubier JA, Sproule TJ, Alley LM, Webb CM, Fine J-D, Roopenian DC, et al. A mouse model of generalized non-Herlitz junctional epidermolysis bullosa. J Investig Dermatol. 2010;130:1819–28.
Fine JD. Inherited epidermolysis bullosa: past, present, and future. Ann NY Acad Sci 2010;1194:213–22.
Kiritsi D, Kern JS, Schumann H, Kohlhase J, Has C, Bruckner-Tuderman L. Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosa. J Med Genet. 2011;48:450–7.
Mabuchi E, Umegaki N, Murota H, Nakamura T, Tamai K, Katayama I. Oral steroid improves bullous pemphigoid-like clinical manifestations in non-Herlitz junctional epidermolysis bullosa with COL17A1 mutation. Br J Dermatol. 2007;157:596–8.
Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986–2006. J Am Acad Dermatol. 2009;60:203–11.
Mallipeddi R. Epidermolysis bullosa and cancer. Clin Exp Dermatol. 2002;27:616–23.
Fine J-D. Squamous cell carcinoma and junctional epidermolysis bullosa. J Am Acad Dermatol. 2012;66:856–7.
Youn J-I, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010;40:2969–75.
Van Deventer HW, Burgents JE, Wu QP, Woodford RMT, Brickey WJ, Allen IC, et al. The inflammasome component Nlrp3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res. 2010;70:10161–9.
Williams SE, Beronja S, Pasolli HA, Fuchs E. Asymmetric cell divisions promote Notch-dependent epidermal differentiation. Nature. 2011;470:353–8.
Chen R, Ning G, Zhao M, Fleming MG, Diaz La, Werb Z, et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Investig. 2001;108:1151–8.
Chen R, Fairley Ja, Zhao M-L, Giudice GJ, Zillikens D, Diaz La, et al. Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation. J Immunol. 2002;169:3987–92.
Bruce DW, Stefanski HE, Vincent BG, Dant TA, Reisdorf S, Bommiasamy H, et al. Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease. J Clin Investig. 2017;127:1813–25.
Acknowledgements
We thank Dr. Dennis Loop for providing the Krt-14 promoter driven Cre mice. We thank Dr. Donna Culton and Susan McCray for assistance in Flow Cytometry. We thank Dr. Yisong Wan and Dr. Jenny PY Ting for their assistance. We thank the UNC Flow Cytometry Core Facility, which is supported in part by P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center, for their assistance in flow cytometry analyses. This work was supported by the NIH (R01 AI40768 and R01 AR072694 to ZL), the 15 UNC Cancer Center Research Award (to ZL) and UNC Graduate School Dissertation 16 Completion Fellowship (to BJH) and P01CA206980 (to NT).
Authors contributions
Conception and design: BJH, MS, NL, ZL. Development of methodology: BJH, JB, SW. Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): BJH, JB, ZL, JC, CCS, ZY. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): BJH, JB, YS, MS, NL, NT, ZL. Writing, review, and/or revision of the manuscript: BJH, YS, ZY, JC, MS, NL, NT, ZL. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): PG, SB, KL, YS, BJH. Study supervision: MS, NL, ZL.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Hwang, BJ., Zhang, Y., Brozowski, J.M. et al. The dysfunction of BP180/collagen XVII in keratinocytes promotes melanoma progression. Oncogene 38, 7491–7503 (2019). https://doi.org/10.1038/s41388-019-0961-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-019-0961-9
This article is cited by
-
Role of adhesion molecules in cancer and targeted therapy
Science China Life Sciences (2024)
-
Melanoma is associated with an increased risk of bullous pemphigoid: a large population-based longitudinal study
Archives of Dermatological Research (2022)